Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1984 1
1990 1
1993 2
1995 2
1997 2
1999 1
2000 3
2001 1
2002 1
2003 4
2004 3
2005 4
2007 2
2009 1
2010 1
2011 2
2012 1
2014 3
2015 5
2016 3
2017 7
2018 2
2019 6
2020 6
2021 4
2022 2
2023 1
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

70 results

Results by year

Filters applied: . Clear all
Page 1
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A; ASPIRE Investigators. Stewart AK, et al. N Engl J Med. 2015 Jan 8;372(2):142-52. doi: 10.1056/NEJMoa1411321. Epub 2014 Dec 6. N Engl J Med. 2015. PMID: 25482145 Free article. Clinical Trial.
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M; OPTIMISMM trial investigators. Richardson PG, et al. Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13. Lancet Oncol. 2019. PMID: 31097405 Clinical Trial.
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Macé S, Corzo KP, Campana F, Le-Guennec S, Dubin F, Anderson KC; ICARIA-MM study group. Attal M, et al. Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14. Lancet. 2019. PMID: 31735560 Clinical Trial.
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG; TOURMALINE-MM1 Study Group. Moreau P, et al. N Engl J Med. 2016 Apr 28;374(17):1621-34. doi: 10.1056/NEJMoa1516282. N Engl J Med. 2016. PMID: 27119237 Free article. Clinical Trial.
Insights on Multiple Myeloma Treatment Strategies.
Mateos MV, Ludwig H, Bazarbachi A, Beksac M, Bladé J, Boccadoro M, Cavo M, Delforge M, Dimopoulos MA, Facon T, Geraldes C, Goldschmidt H, Hájek R, Hansson M, Jamroziak K, Leiba M, Masszi T, Mendeleeva L, O'Dwyer M, Plesner T, San-Miguel JF, Straka C, van de Donk NWCJ, Yong K, Zver S, Moreau P, Sonneveld P. Mateos MV, et al. Among authors: mendeleeva l. Hemasphere. 2018 Dec 27;3(1):e163. doi: 10.1097/HS9.0000000000000163. eCollection 2019 Feb. Hemasphere. 2018. PMID: 31723802 Free PMC article. Review.
Current multiple myeloma treatment strategies with novel agents: a European perspective.
Ludwig H, Beksac M, Bladé J, Boccadoro M, Cavenagh J, Cavo M, Dimopoulos M, Drach J, Einsele H, Facon T, Goldschmidt H, Harousseau JL, Hess U, Ketterer N, Kropff M, Mendeleeva L, Morgan G, Palumbo A, Plesner T, San Miguel J, Shpilberg O, Sondergeld P, Sonneveld P, Zweegman S. Ludwig H, et al. Among authors: mendeleeva l. Oncologist. 2010;15(1):6-25. doi: 10.1634/theoncologist.2009-0203. Epub 2010 Jan 19. Oncologist. 2010. PMID: 20086168 Free PMC article. Review.
Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation.
Mohty M, Hübel K, Kröger N, Aljurf M, Apperley J, Basak GW, Bazarbachi A, Douglas K, Gabriel I, Garderet L, Geraldes C, Jaksic O, Kattan MW, Koristek Z, Lanza F, Lemoli RM, Mendeleeva L, Mikala G, Mikhailova N, Nagler A, Schouten HC, Selleslag D, Suciu S, Sureda A, Worel N, Wuchter P, Chabannon C, Duarte RF. Mohty M, et al. Among authors: mendeleeva l. Bone Marrow Transplant. 2014 Jul;49(7):865-72. doi: 10.1038/bmt.2014.39. Epub 2014 Mar 31. Bone Marrow Transplant. 2014. PMID: 24686988 Review.
[Detection of paraprotein in plasma cell tumors].
Rekhtina IG, Mendeleeva LP, Soboleva NP, Dubina IA, Pervakova MI, Lapin SV. Rekhtina IG, et al. Among authors: mendeleeva lp. Ter Arkh. 2022 Jan 15;94(1):135-144. doi: 10.26442/00403660.2022.01.201326. Ter Arkh. 2022. PMID: 36286929 Russian.
[Invasive pulmonary aspergillesis].
Kliasova GA, Petrova NA, Parovichnikova EN, Gotman LN, Isaev VG, Mikhaĭlova EA, Ustinova EN, Khoroshko ND, Vishnevskaia ES, Kremenetskaia AM, Kravchenko SK, Kaplanskaia IB, Kokhno AA, Ptitsin SA, Liubimova LS, Mendeleeva LP, Mitish NE, Galstian GM, Ryzhko VV, Tochenov AV, Savchenko VG. Kliasova GA, et al. Among authors: mendeleeva lp. Ter Arkh. 2005;77(7):65-71. Ter Arkh. 2005. PMID: 16116913 Russian.
70 results